Henry Schein reaffirms $125m savings target and 2026 guidance despite medical softness
Executives at Henry Schein highlighted continued strength in its dental segment and a pivot toward helping customers generate revenue, even as medical sales faced headwinds from a weak respiratory illness season.
Henry Schein has reaffirmed its $125 million net run-rate value creation goal for the end of 2026 and maintained its full-year financial guidance, signalling confidence in its operational improvement plans despite near-term softness in medical sales. Speaking at a Bank of America healthcare technology and distribution event, Chief Executive Officer Fred Lowery and Chief Financial Officer Ron South outlined a strategy focused on gross profit optimisation and a fundamental shift in the company’s customer value proposition.
Lowery, who has been in the role for approximately two months, reported continued momentum in the dental business during April and May, describing the first quarter as having healthy growth in dental and strong expansion in technology and distribution. He emphasised that the company is moving away from a messaging framework centred on helping customers save money, towards a model that assists them in making more money, growing faster, and operating more productively. This commercial alignment is a key component of his 100-day plan, which also prioritises artificial intelligence to accelerate new product development and enhance technology capabilities.
Medical sales experienced a slowdown attributed to a weaker-than-expected respiratory illness season, which reduced demand for flu and RSV diagnostics. However, management noted that underlying medical growth excluding these specific diagnostics remained in the mid-single digits. South explained that point-of-care diagnostic kit sales typically weigh on performance in the first and fourth quarters, and he expects less seasonal impact in the middle of the year as the respiratory season wanes.
The company expects the majority of its $125 million cost savings to ramp in the second half of 2026, driven by general and administrative initiatives and gross profit optimisation strategies. South noted that gross profit optimisation is expected to contribute sooner than administrative savings, with some benefits already visible in the first quarter. These initiatives include dynamic pricing and growth in private label products, which carry better gross margins than the overall portfolio and are expected to provide sustainable margin improvement.
Beyond core operations, Henry Schein highlighted several growth vectors, including its home solutions business, which now accounts for more than 10% of medical revenue with a run rate exceeding $400 million. The segment is growing faster and delivering better margins than core medical. In the specialty segment, growth was approximately 8%, with local internal growth at 1.7%. The acquisition of the S.I.N. U.S. distributor has also provided greater control over its value implant portfolio, which is outpacing premium implants in growth.
Lowery identified dental service organisations (DSOs) as a significant area for expanded partnership, particularly regarding corporate brands and practice management software. He stated that the company expects to expand corporate brand share with DSOs over multiple years rather than through quick, one-time shifts. South confirmed that Henry Schein will remain disciplined on mergers and acquisitions, focusing on higher-growth, higher-margin areas such as specialty products, technology, and value-added services.
